Literature DB >> 10871344

Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model.

A Carnero1, J D Hudson, G J Hannon, D H Beach.   

Abstract

Using an improved system for the functional identification of active antisense fragments, we have isolated antisense fragments which inactivate the p53 tumour suppressor gene. These antisense fragments map in two small regions between nt 350 and 700 and nt 800 and 950 of the coding sequence. These antisense fragments appear to act by inhibition of p53 mRNA translation both in vivo and in vitro. Expression of these antisense fragments overcame the p53-induced growth arrest in a cell line which expresses a thermolabile mutant of p53 and extended the in vitro lifespan of primary mouse embryonic fibroblasts. Continued expression of the p53 antisense fragment contributed to immortalisation of primary mouse fibroblasts. Subsequent elimination of the antisense fragment in these immortalised cells led to restoration of p53 expression and growth arrest, indicating that immortal cells continuously require inactivation of p53. Expression of MDM2 or SV40 large T antigen, but not E7 nor oncogenic ras, overcomes the arrest induced by restoration of p53 expression. Functional inactivation of both p21 and bax (by overexpression of Bcl2), but not either alone, allowed some bypass of p53-induced growth arrest, indicating that multiple transcriptional targets of p53 may mediate its antiproliferative action. The ability to conditionally inactivate and subsequently restore normal gene function may be extremely valuable for genetic analysis of genes for which loss-of-function is involved in specific phenotypes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871344      PMCID: PMC102629          DOI: 10.1093/nar/28.11.2234

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  57 in total

Review 1.  Mechanism of action of antisense RNA. Sometime inhibition of transcription, processing, transport, or translation.

Authors:  D T Denhardt
Journal:  Ann N Y Acad Sci       Date:  1992-10-28       Impact factor: 5.691

Review 2.  Antisense therapy for cancer.

Authors:  T Mukhopadhyay; J A Roth
Journal:  Cancer J Sci Am       Date:  1995 Nov-Dec

3.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

4.  Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype.

Authors:  Y Zhang; T Mukhopadhyay; L A Donehower; R N Georges; J A Roth
Journal:  Hum Gene Ther       Date:  1993-08       Impact factor: 5.695

5.  Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts.

Authors:  E M Rogan; T M Bryan; B Hukku; K Maclean; A C Chang; E L Moy; A Englezou; S G Warneford; L Dalla-Pozza; R R Reddel
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

6.  Escape from senescence in human diploid fibroblasts induced directly by mutant p53.

Authors:  J A Bond; F S Wyllie; D Wynford-Thomas
Journal:  Oncogene       Date:  1994-07       Impact factor: 9.867

7.  Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance and cell immortalization.

Authors:  A V Gudkov; A R Kazarov; R Thimmapaya; S A Axenovich; I A Mazo; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.

Authors:  A V Gudkov; C R Zelnick; A R Kazarov; R Thimmapaya; D P Suttle; W T Beck; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

Review 9.  p53 and human cancers.

Authors:  D P Lane
Journal:  Br Med Bull       Date:  1994-07       Impact factor: 4.291

Review 10.  p53 loss of function: implications for the processes of immortalization and tumorigenesis.

Authors:  C A Finlay
Journal:  Bioessays       Date:  1992-08       Impact factor: 4.345

View more
  13 in total

Review 1.  Translational approaches targeting the p53 pathway for anti-cancer therapy.

Authors:  Frank Essmann; Klaus Schulze-Osthoff
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

2.  ARF stimulates XPC to trigger nucleotide excision repair by regulating the repressor complex of E2F4.

Authors:  Carmen Dominguez-Brauer; Yi-Ju Chen; Patrick M Brauer; Julia Pimkina; Pradip Raychaudhuri
Journal:  EMBO Rep       Date:  2009-07-31       Impact factor: 8.807

3.  MAP17, a ROS-dependent oncogene.

Authors:  Amancio Carnero
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

4.  Cellular senescence as a target in cancer control.

Authors:  Mar Vergel; Juan J Marin; Purificacion Estevez; Amancio Carnero
Journal:  J Aging Res       Date:  2010-12-30

5.  Immortalization of MEF is characterized by the deregulation of specific miRNAs with potential tumor suppressor activity.

Authors:  Milena Rizzo; Monica Evangelista; Marcella Simili; Laura Mariani; Letizia Pitto; Giuseppe Rainaldi
Journal:  Aging (Albany NY)       Date:  2011-07       Impact factor: 5.682

6.  Characterization of the p53 response to oncogene-induced senescence.

Authors:  Lidia Ruiz; Magali Traskine; Irene Ferrer; Estrella Castro; Juan F M Leal; Marcelline Kaufman; Amancio Carnero
Journal:  PLoS One       Date:  2008-09-18       Impact factor: 3.240

7.  The proto-oncogene LRF is under post-transcriptional control of MiR-20a: implications for senescence.

Authors:  Laura Poliseno; Letizia Pitto; Marcella Simili; Laura Mariani; Luisa Riccardi; Alessia Ciucci; Milena Rizzo; Monica Evangelista; Alberto Mercatanti; Pier Paolo Pandolfi; Giuseppe Rainaldi
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

8.  Gaining insights into the codon usage patterns of TP53 gene across eight mammalian species.

Authors:  Tarikul Huda Mazumder; Supriyo Chakraborty
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

9.  Cell Cycle Regulatory Protein Expression in Multinucleated Giant Cells of Giant Cell Tumor of Bone: do They Proliferate?

Authors:  Mate E Maros; Peter Balla; Tamas Micsik; Zoltan Sapi; Miklos Szendroi; Holger Wenz; Christoph Groden; Ramses G Forsyth; Piero Picci; Tibor Krenacs
Journal:  Pathol Oncol Res       Date:  2021-05-03       Impact factor: 3.201

10.  A dual-color fluorescence-based platform to identify selective inhibitors of Akt signaling.

Authors:  Aranzazú Rosado; Fabian Zanella; Beatriz Garcia; Amancio Carnero; Wolfgang Link
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.